PPIPT00989
Target Protein Information
| Protein_Name | Cellular tumor antigen p53 |
|---|---|
| Protein_Sequence | MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD |
| Organism_Source | Homo sapiens |
| Functional_Classification | Tumor suppressor transcription factor |
| Cellular_Localization | Nucleus |
| Gene_Names | TP53 |
| UniProt_ID | P04637 |
| Protein-Protein Interaction Networks | |
Peptide Basic Information
| Peptide_Name | PCAP-409 |
|---|---|
| Peptide_Sequence | HSTPHPD |
| Peptide_Length | 7 |
| Peptide_SMILES | C[C@@H](O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O |
| Chemical_Modification | None |
| Cyclization_Method | None |
| Linear/Cyclic | Cyclic |
| N-terminal_Modification | myristoylation |
| C-terminal_Modification | Free |
| Amino_Acid_Distribution | |
|
|
|
Peptide Physicochemical
| Molecular_Weight | 789.80 |
|---|---|
| Aliphatic_Index | 0.00000 |
| Aromaticity | 0.00000 |
| Average_Rotatable_Bonds | 2.71429 |
| Charge_at_pH_7 | -0.81975 |
| Isoelectric_point | 6.49650 |
|---|---|
| Number_of_Hydrogen_Bond_Acceptors | 13 |
| Number_of_Hydrogen_Bond_Donors | 11 |
| Topological_Polar_Surface_Area | 355.46000 |
| X_logP_energy | -4.90110 |
Interaction Information
| Affinity | KD=390 nM |
|---|---|
| Affinity_Assay | MicroScale Thermophoresis |
| PDB_ID | None |
| Type | Affinity ligand |
| Structure | |
Reference Information
| Document_Type | Patent |
|---|---|
| Title | PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 |
| Release_Year | 2019 |
| Patent_ID | US20190048053A1 |